Windtree Therapeutics, Inc. (Formerly Known As Discovery Laboratories, Inc.)

390 articles about Windtree Therapeutics, Inc. (Formerly Known As Discovery Laboratories, Inc.)

• Windtree Therapeutics Reports First Quarter 2020 Financial Results and Provides Key Business Updates

  5/14/2020

  Windtree Therapeutics, Inc. (OTCQB: WINTD), a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute cardiovascular and pulmonary diseases, today reported financial results for the first quarter ended March 31, 2020 and provided key business updates. 

• Windtree Announces First Patient Enrolled in AEROSURF® Bridging Study for the Treatment of Respiratory Distress Syndrome

  4/29/2020

  Windtree Therapeutics, Inc. (OTCQB: WINT), a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute cardiovascular and pulmonary diseases, today announced it has enrolled the first patient into its AEROSURF® phase 2b bridging study in premature inf

• Windtree Therapeutics Announces Reverse Stock Split - April 28, 2020

  4/28/2020

  Windtree Therapeutics, Inc., a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute cardiovascular and pulmonary diseases, announced a 1-for-3 reverse stock split of its issued and outstanding common stock.

• Windtree Presents New Istaroxime Phase 2b Study Analysis at the American College of Cardiology (ACC) Congress

  4/6/2020

  Windtree Therapeutics, Inc. (OTCQB: WINT), today announced the presentation of a new subset analysis from a phase 2b study of istaroxime in patients hospitalized with acute heart failure (AHF) at the American College of Cardiology (ACC) 2020 virtual meeting

• Windtree Therapeutics Reports Fourth Quarter 2019 Financial Results and Provides Key Business Updates

  4/3/2020

  Windtree Therapeutics, Inc., a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute cardiovascular and pulmonary diseases, reported financial results for the fourth quarter ended December 31, 2019 and provided key business updates.

• Windtree Enters into Agreement with Lee's Pharmaceutical for Non-Dilutive Funding of the Continued Development of AEROSURF®

  3/31/2020

  Windtree Therapeutics, Inc. announces it has entered into a binding term sheet (the "Term Sheet") with Lee's Pharmaceutical Holdings (HK) Ltd

• Windtree to Pursue Clinical Study of Lung Injury Treatment in COVID-19 Patients with its KL4 Surfactant Therapy

  3/24/2020

  Windtree Therapeutics, Inc., a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute cardiovascular and pulmonary diseases, announced it is planning to study its proprietary KL4 surfactant to potentially mitigate the pulmonary effects of severe COVID-19 infection.

• Windtree Therapeutics Completes $26.4 Million Private Placement

  12/9/2019

  Windtree Therapeutics, Inc. (OTCQB: WINT), a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute cardiovascular and pulmonary diseases, today announced that it has completed a $26.4 million private placement of common stock and warrants.

• Windtree to Host a Conference Call on December 11, 2019 to Provide Development Programs and Financial Update

  12/9/2019

  Conference Call and Webcast Scheduled for Wednesday, December 11 at 8:00 a.m. EST

• Windtree Therapeutics Provides Business Update

  10/25/2019

  Windtree Therapeutics, Inc. (OTCQB: WINT), a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute cardiovascular and pulmonary diseases, today provided updates on its lead development programs and business operations.

• Windtree Therapeutics Announces Publication of Results of Lung Deposition Study of Aerosolized Lucinactant

  9/6/2019

   Windtree Therapeutics, Inc. (OTCQB: WINT), today announced the full publication of previously described results of a lung deposition study conducted in non-human primates (NHPs) that demonstrated the Company's proprietary aerosol delivery system (ADS) is capable of delivering aerosolized lucinactant (the Company's lyophilized KL4 surfactant) throughout all regions of the lung.

• Windtree Therapeutics Reports Second Quarter 2019 Financial Results and Provides Key Business Updates

  8/14/2019

  Windtree Therapeutics, Inc. (OTCQB: WINT), a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute cardiovascular and pulmonary diseases, today reported financial results for the second quarter ended June 30, 2019 and provided key business updates. 

• Windtree Announces FDA Fast Track Designation for Istaroxime

  8/13/2019

  Windtree Therapeutics, Inc. (OTCQB: WINT), a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute cardiovascular and pulmonary diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for istaroxime for the treatment of acute heart failure.

• Windtree Therapeutics to Host Research & Development Day in New York City on June 25

  6/19/2019

  Windtree Therapeutics, Inc. announced that it will host a research and development day in New York City on Tuesday, June 25 from 8:00 am – 9:30 am EDT.

• Windtree and Eleison Announce Initial Results of Delivering Inhaled Lipid Cisplatin (ILC) Utilizing Windtree's Drug Delivery Technology

  6/4/2019

  Results Demonstrate Feasibility to Aerosolize ILC for Use in Thoracic Oncology Treatment

• Istaroxime Phase 2b Study Results Presented in Late Breaker Clinical Trial Session at the ESC Heart Failure Congress

  5/30/2019

  Istaroxime Demonstrated Significantly Improved Cardiac Function in Patients with Acute Heart Failure

• Windtree Therapeutics Reports First Quarter 2019 Financial Results and Provides Key Business Updates

  5/20/2019

  Windtree Therapeutics, Inc. (OTCQB: WINT), a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute cardiovascular and pulmonary diseases, today reported financial results for the first quarter ended March 31, 2019 and provided key business updates. 

• New Phase 2b Analysis Suggests AEROSURF® may Reduce Incidence and Severity of Bronchopulmonary Dysplasia in Preterm Infants with RDS

  5/10/2019

  New Post-Hoc Analysis Presented at the Pediatric Academic Societies (PAS) Meeting

• Windtree Therapeutics Appoints Daniel Geffken to Board of Directors

  4/30/2019

  Windtree Therapeutics, Inc., announced it has appointed Daniel Geffken to the Company's Board of Directors, effective April 24, 2019.

• Windtree Therapeutics to Hold Investor Call Thursday, January 3, 2019 at 8:00 a.m. EST

  1/2/2019

  Previously Announced Call to Discuss Merger with CVie Therapeutics, $39 Million Private Placement, New Products Overview and Plans for 2019